Tarsus Pharmaceuticals (NASDAQ:TARS) Releases Earnings Results, Beats Estimates By $0.27 EPS

Tarsus Pharmaceuticals (NASDAQ:TARS) issued its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.27, FiscalAI reports. The firm had revenue of $162.05 million for the quarter, compared to the consensus estimate of $150.30 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS traded down $0.25 during trading hours on Wednesday, hitting $64.79. 931,710 shares of the company were exchanged, compared to its average volume of 564,715. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. Tarsus Pharmaceuticals has a 52-week low of $38.51 and a 52-week high of $85.25. The company’s 50 day moving average price is $69.03 and its 200-day moving average price is $72.00. The stock has a market capitalization of $2.79 billion, a price-to-earnings ratio of -39.99 and a beta of 0.52.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Elizabeth Yeu Lin sold 390 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $26,130.00. Following the completion of the sale, the insider directly owned 23,308 shares in the company, valued at approximately $1,561,636. The trade was a 1.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, General Counsel Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $283,477.00. Following the sale, the general counsel owned 63,959 shares of the company’s stock, valued at approximately $4,285,253. The trade was a 6.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 79,391 shares of company stock worth $5,432,035. Corporate insiders own 8.97% of the company’s stock.

Institutional Trading of Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. State of Wisconsin Investment Board lifted its stake in Tarsus Pharmaceuticals by 1.1% during the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock valued at $2,613,000 after acquiring an additional 332 shares during the period. Federated Hermes Inc. lifted its stake in Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after acquiring an additional 339 shares during the period. Creative Planning lifted its stake in Tarsus Pharmaceuticals by 3.3% during the 3rd quarter. Creative Planning now owns 12,367 shares of the company’s stock valued at $735,000 after acquiring an additional 393 shares during the period. Truvestments Capital LLC lifted its stake in Tarsus Pharmaceuticals by 106.1% during the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after acquiring an additional 468 shares during the period. Finally, Franklin Resources Inc. lifted its stake in Tarsus Pharmaceuticals by 3.6% during the 3rd quarter. Franklin Resources Inc. now owns 22,183 shares of the company’s stock valued at $1,318,000 after acquiring an additional 781 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on TARS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. Zacks Research downgraded shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. The Goldman Sachs Group reissued a “neutral” rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Finally, Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They set an “outperform” rating and a $98.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $90.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.